Labcorp at AASLD Contact Form

PGDx elio™ Tissue Complete (ETC) is a comprehensive tumor profiling next generation sequencing (NGS) kitted solution. NGS-based solutions often involve complex protocols with multiple touchpoints that might benefit from automation.

The PGDx elio™ Plasma Focus Dx is a highly specific, sensitive, reproducible, and accurate hybrid capture-based next-generation sequencing (NGS) assay optimized for cell-free DNA with excellent performance in analytical validation studies across various variant types and solid tumor types.

The Labcorp Plasma Focus test demonstrated a 95.8% success rate and was able to detect clinically actionable variants across various cancer types, with rapid reporting for the majority of cases, highlighting its effectiveness in informing precision oncology decision-making.

The TSO500 HT assay has been effectively validated to genotype HLA-A, -B, and -C from tumor samples, providing valuable tumor-informed HLA allele haplotypes with high accuracy, which can aid clinicians and drug developers in selecting HLA-directed therapies and enrolling patients in HLA-restricted clinical trials across various tumor types, includ

The use of LAG-3 expression as a clinical biomarker to select for patients who might benefit from anti-LAG-3 immuniotherapies might require multiple rapid, sensitive, and accurate assays.